1 / 20

Development and Justification of Qualification Threshold

This article discusses the decision criteria and process for setting a qualification threshold (QT) in toxicity assessment. It compares QT to non-carcinogenic reference thresholds and considers factors such as irritation, hypersensitivity, and age. Examples from marketed products are provided to illustrate the application of QT.

mossr
Download Presentation

Development and Justification of Qualification Threshold

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Development and Justification of Qualification Threshold Ron Wolff IPAC-RS Representative Fellow, Life Sciences Nektar Therapeutics

  2. Outline • Decision criteria • Process for setting qualification threshold (QT) • Comparison to non-carcinogenic reference thresholds in a similar manner to SCT • Consideration of irritation, hypersensitivity, age • Relation of QT to • Ambient particulate matter • Examples from marketed products

  3. Decision Criteria • A leachable with a tolerable daily intake (TDI) at or below the qualification threshold • would have a dose so low as to present negligible safety concerns from noncarcinogenic toxic effects • would be considered qualified, so no toxicological assessment would be required • would require a toxicology risk assessment with a structural alert or known class effect for carcinogenicity/genotoxicity, irritation, or hypersensitivity

  4. Reference Exposure Levels (RELs) • Definition • Daily exposure concentration considered to present negligible risk to human health from non-carcinogenic effects • Usually a no-observed-adverse-effect-level (NOAEL) from animal toxicology studies with the use of an appropriate safety factor (usually  100) • Sources • US EPA • Agency for Toxic Substances Disease Registry (ATSDR) • California Environmental Protection Agency (CAL EPA)

  5. 100% 100% Systemic Tox (N=44) Systemic Tox (N=41) Respiratory Tox (N=32) Respiratory Tox (N=18) 80% 80% 60% 60% 40% 40% 20% 20% 0% 0% 0.0001 0.01 1 100 10000 1000000 0.0001 0.01 1 100 10000 1000000 ATSDR Minimal Risk Level (µg/day) California REL (µg/day) 100% 100% Systemic Tox (N=62) Systemic Tox (N=98) Respiratory Tox (N=38) 80% 80% Respiratory Tox (N=57) 60% 60% 40% 40% 20% 20% 0% 0% 0.0001 0.01 1 100 10000 1000000 0.0001 0.01 1 100 10000 1000000 US EPA Inhalation RfD (µg/day) Combined Reference Value (µg/day) Inhalation Reference Levels in Various Databases

  6. Summary of Inhalation Reference Toxicity Values (µg/day)

  7. Most Compounds with Reference Levels < 5 g/day Are Metals, Carcinogens or Identified Irritants

  8. Irritation • Evaluated from the point of view that asthmatics are the most sensitive population • Used the RD50 database developed on inhaled irritants in mice as a starting point • Validated, well-accepted, extensive database of commodity chemicals • RD50 is the concentration that produces marked effects in mice by reducing respiratory frequency by 50% • Confluence of data suggest that 0.001 X RD50 is a safe concentration for most asthmatics • Corresponds to a concentration that produces no discernible effects on lung tissue, and thus also unlikely to elicit any bronchoconstrictor response, since the two are correlated • RD50 based safe dose = 0.001 X RD50 breathed for 10 minutes

  9. Sensitivity of Asthmatics Compared to Normal Population • Cockcroft (Ann Allergy, 1985) studied 253 normals and 181 symptomatic asthmatics challenged with aerosolized histamine • 25% of normals responded at a concentration of 16 mg/L [effectively, an RD50 concentration] • 25% of asthmatics responded at 0.2 mg/L • No observable responses in asthmatics at 0.015 mg/L Illustrates that 1/1000 of RD50 values is likely to pose negligible risk for most asthmatics

  10. RD50 Based Safe Dose in Asthmatics is Less than Occupational Short Term Exposure Limits (STELs)

  11. RD50 Based Safe Doses are Similar to California RELs Designed to Protect the General Population (Including Sensitive Sub-Populations)

  12. Hypersensitivity • Data on isocyanates used to provide perspective • RD50 of toluene diisocyanate is 0.4 ppm • Permissible Exposure Level (PEL) is 0.02 ppm • Level designated to prevent induction of sensitization • Lowest concentration eliciting responses in sensitized subjects • 0.001 ppm These data and other similar examples suggest that 0.001 X RD50 is also protective of hypersensitivity reactions

  13. Acute Irritation and Sensitization Have Similar Dose-Response to Chronic Respiratory Toxicity

  14. Most Compounds with RD50 Based Reference Exposure Levels < 5 g/day Can be Identified with Structural Alerts • Isocyanates • Aldehydes • Pesticides • Nitriles • Styrenes

  15. Comparison of 5 g/day QT with Ambient Particulate Exposures • Ambient reference concentration - 18 g/m3 • Data from Portage, Wisconsin • Cleanest environment in the “Six cities study” • Best air quality and least cardio-respiratory disease • Designated as the “control” city against which others were compared • Well below the National Air Quality Standards for PM10 (respirable fraction) • 50 g/m3 annual average • 150 g/m3 twenty-four hr average

  16. QT of 5 µg/day Compared to Inhaled Particulate in the Cleanest of the “Six Cities”

  17. Perspective for Exposures to Children • 5 g/day QT • Represents a minor additional load compared to daily environmental exposure for any age group, including children • Comparisons of toxicokinetics in adults and children are within the toxicokinetic safety factor of 3.16 greater than 90% of the time • Comparison of deposition of particles and gases in adults vs children are within the toxicokinetic safety factor of 3.16 Therefore, the standard intraspecies safety factor of 10 (toxicokinetic factor of 3.16 x toxicodynamic factor of 3.16) appears to be adequate to account for possible differences between adults and children, however additional research in this area is warranted

  18. Comparison of 5 µg/dayQT with ICH Thresholds

  19. OINDP L&E Threshold Perspective • Recommended thresholds based on dose inhaled by patients • Rather than a percentage (%) as in ICH Guidelines • 5 g/day QT • Recommendations intermediate between API and drug product ranges • Relevance maximized based on considerations of • Total daily intake • Structural alerts • Conservative risk assessment

  20. Summary • A Qualification Threshold (QT) of 5 µg/daymeets the criterion of a dose that is sufficiently low as to present negligible safety concerns for noncarcinogenic toxic effects. • Consideration of possible irritancy and hypersensitivity suggest that 5 µg/day will adequately protect sensitive sub-populations • The risk assessment must include structural alert information to provide case-by-case assessments for metals, isocyanates, aldehydes, nitriles, and styrenes whose levels are below the QT

More Related